JLPC(SH:600513)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was CNY 528,755,530.24, representing a year-on-year increase of 2.55%[3] - The net profit attributable to shareholders for Q3 2023 was CNY 27,314,035.33, a decrease of 18.78% compared to the same period last year[3] - The basic earnings per share for Q3 2023 was CNY 0.10, down 16.67% year-on-year[3] - In Q3 2023, the company's net profit was CNY 100,597,014.28, a decrease of 16.5% compared to CNY 120,423,496.23 in Q3 2022[14] - The company's operating profit for Q3 2023 was CNY 117,398,003.99, down from CNY 141,320,533.90 in the same period last year, reflecting a decline of 16.9%[14] - The total comprehensive income for Q3 2023 was CNY 100,597,014.28, compared to CNY 120,423,496.23 in Q3 2022, showing a decrease of 16.5%[15] Assets and Liabilities - The total assets as of September 30, 2023, were CNY 2,805,467,612.01, reflecting a 3.33% increase from the end of the previous year[3] - Current assets as of September 30, 2023, totaled CNY 1,368,558,285.45, up from CNY 1,339,905,715.11 at the end of 2022, reflecting a growth of approximately 2.93%[10] - Non-current assets increased to CNY 1,465,561,896.90 as of September 30, 2023, compared to CNY 1,346,380,863.88 at the end of 2022, marking a rise of about 8.83%[11] - Total liabilities amounted to CNY 1,338,705,350.02 as of September 30, 2023, up from CNY 1,301,206,939.50 at the end of 2022, indicating a growth of about 2.88%[12] - Shareholders' equity totaled CNY 1,466,762,261.99 as of September 30, 2023, compared to CNY 1,413,732,209.83 at the end of 2022, reflecting an increase of approximately 3.74%[12] Cash Flow - The net cash flow from operating activities for the year-to-date period was CNY -10,645,088.02, with a significant increase in sales collections compared to the previous year[4] - The net cash flow from operating activities for Q3 2023 was negative at CNY -10,645,088.02, an improvement from CNY -28,877,037.46 in Q3 2022[18] - The company’s investment activities resulted in a net cash outflow of CNY -131,701,882.68 in Q3 2023, compared to CNY -162,644,694.93 in Q3 2022, indicating a reduction in cash outflow[18] Operating Costs and Revenue - Total operating revenue for the first three quarters of 2023 reached CNY 1,483,405,300.86, an increase from CNY 1,412,283,517.33 in the same period of 2022, representing a growth of approximately 5.03%[13] - Total operating costs for the first three quarters of 2023 were CNY 1,371,969,771.26, compared to CNY 1,272,183,006.75 in 2022, indicating an increase of about 7.83%[13] - The total revenue from operating activities for the first three quarters of 2023 was CNY 1,590,963,477.35, compared to CNY 1,510,823,020.76 in the same period of 2022, marking an increase of 5.3%[17] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,782[5] - The largest shareholder, Jiangsu Lianhuan Pharmaceutical Group Co., Ltd., holds 37.86% of the shares[6] Research and Development - Research and development expenses increased to CNY 69,041,803.18 in Q3 2023, up from CNY 58,937,451.98 in Q3 2022, representing an increase of 17.5%[14] Strategic Initiatives - The company is focusing on expanding its market presence and investing in new product development to drive future growth[13] - The company plans to enhance its operational efficiency through strategic initiatives aimed at cost reduction and improved resource allocation[13] Government Support - The company reported government subsidies amounting to CNY 112,172.80 during the reporting period[6] Non-recurring Gains and Losses - The company did not recognize any non-recurring gains or losses during the reporting period[4] Return on Equity - The weighted average return on equity for Q3 2023 was 2.11%, a decrease of 0.68 percentage points compared to the same period last year[3]